CERTIFICATION UNDER 37 CFR 1.10

Mereby certify that this paper and any documents referred to as enclosed or attached are being deposited with the United States Postal Service on this date in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL897831575US addressed to:

Commissioner of Patents Washington, D.C. 20231 Box IDS-Non Fee

on /2/13/0/ Date

Signature of Person Making Deposit

Bonnie Ferguson

Printed Name of Person Making Deposit

Applicant: Burk et al

Title: METHOD AND COMPOSITIONS FOR TREATMENT OF OCULAR

NEOVASCULARIATION AND NEURAL INJURY

Allergan Docket: 17400CIP(BAR)

Enclosed Are:

Certification Under 37 CFR 1.10 (Express Mail Label No. EL897831575US

- 1. POSTCARD
- 2. CERTIFICATE OF MAILING BY EXPRESS MAIL
- 3. INFORMATION DISCLOSURE STATEMENT
- 4. PTO 1449 WITH REFERENCES

0360

OFF O

PATENT

17400CIP(BAR)
PE CONTROL IN THE U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

) Group Art Unit: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EL897831575US) in an envelope addressed to: Box IDS-Non-Fee,Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit: /2/13/0/
Person making Deposit: BONNE FEREUSON
Signature: Date of Signature

For: Methods and Compositions for Treatment of Ocular Neo-Vascularization and Neural Injury

Examiner: Not yet assigned

Serial No.: 09/998,718

Filed: Herewith

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: $\frac{12}{13}$

Carlos A. Fisher Reg. No. 36,510

ALLERGAN, INC.

T2-7H

2525 Dupont Drive Irvine, CA 92612

Tel: 714-246-4920 Fax: 714-246-4249